Index -
P/E 2.13
EPS (ttm) 5.66
Insider Own 47.68%
Shs Outstand 733.33M
Perf Week -0.20%
Market Cap 8.78B
Forward P/E -
EPS next Y -1.07
Insider Trans -2.33%
Shs Float 380.88M
Perf Month 3.57%
Income 4.81B
PEG -
EPS next Q -0.25
Inst Own 67.73%
Short Float 12.55%
Perf Quarter 0.97%
Sales 125.68M
P/S 69.83
EPS this Y -114.43%
Inst Trans 6.82%
Short Ratio 8.02
Perf Half Y 11.52%
Book/sh 7.03
P/B 1.72
EPS next Y -41.98%
ROA 117.35%
Short Interest 47.81M
Perf Year 16.48%
Cash/sh 7.40
P/C 1.63
EPS next 5Y -
ROE 159.08%
52W Range 9.69 - 13.06
Perf YTD 7.35%
Dividend Est. -
P/FCF -
EPS past 5Y 0.08%
ROI 92.57%
52W High -7.65%
Beta 1.26
Dividend TTM -
Quick Ratio 10.43
Sales past 5Y 493.24%
Gross Margin 95.96%
52W Low 24.41%
ATR (14) 0.31
Dividend Ex-Date -
Current Ratio 10.43
EPS Y/Y TTM 554.70%
Oper. Margin -895.80%
RSI (14) 50.13
Volatility 2.11% 2.93%
Employees 908
Debt/Eq 0.01
Sales Y/Y TTM 21.84%
Profit Margin 3827.42%
Recom 1.20
Target Price 16.21
Option/Short Yes / Yes
LT Debt/Eq 0.01
EPS Q/Q 20.78%
Payout 0.00%
Rel Volume 0.28
Prev Close 12.11
Sales Surprise -90.26%
EPS Surprise -15.51%
Sales Q/Q -87.94%
Earnings Nov 12 BMO
Avg Volume 5.96M
Price 12.06
SMA20 -0.09%
SMA50 1.77%
SMA200 6.83%
Trades
Volume 637,903
Change -0.45%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-15-24 Initiated
Wolfe Research
Outperform
$17
Jan-05-24 Initiated
Piper Sandler
Overweight
$20
Dec-12-23 Initiated
Deutsche Bank
Buy
$14
Oct-17-23 Initiated
Guggenheim
Buy
$17
Jun-08-23 Initiated
BofA Securities
Neutral
$10.50
Oct-27-22 Initiated
JP Morgan
Overweight
$7
May-23-22 Initiated
SVB Leerink
Outperform
$6
Apr-29-22 Initiated
Cantor Fitzgerald
Overweight
$15
Dec-15-21 Initiated
Goldman
Buy
$15
Nov-08-21 Initiated
H.C. Wainwright
Buy
$14
Oct-28-21 Initiated
Citigroup
Buy
$11
Oct-26-21 Initiated
Truist
Buy
$15
Oct-26-21 Initiated
Jefferies
Buy
$10
Oct-26-21 Initiated
Cowen
Outperform
Show Previous Ratings
Dec-03-24 07:00AM
07:00AM
Nov-15-24 05:01PM
Nov-12-24 07:00AM
Nov-11-24 07:04AM
04:35PM
Loading…
Oct-29-24 04:35PM
Oct-28-24 09:25AM
Sep-18-24 07:30AM
Sep-10-24 06:30AM
06:30AM
Sep-09-24 07:00AM
Sep-04-24 06:55PM
Aug-08-24 07:00AM
Jul-25-24 04:05PM
May-31-24 08:04AM
11:53AM
Loading…
May-30-24 11:53AM
08:20AM
07:00AM
May-27-24 06:28PM
06:13PM
May-16-24 04:05PM
May-08-24 02:43AM
May-07-24 02:04PM
May-01-24 10:47AM
Apr-25-24 08:00AM
Apr-12-24 11:09AM
Apr-02-24 07:00AM
Mar-27-24 01:55PM
(The Wall Street Journal) +7.54%
Mar-26-24 06:22PM
Mar-17-24 08:50AM
07:04AM
Loading…
Mar-14-24 07:04AM
Feb-15-24 02:45AM
Feb-13-24 07:00AM
Feb-10-24 02:55AM
Jan-30-24 04:05PM
Dec-27-23 08:05PM
Dec-20-23 04:30PM
(GlobeNewswire) -7.78%
+5.82%
Dec-14-23 09:00AM
Nov-28-23 07:00AM
02:38AM
Nov-27-23 08:00AM
Nov-14-23 01:00PM
Nov-13-23 07:00AM
Nov-10-23 08:00AM
Oct-30-23 05:30PM
Oct-24-23 08:00AM
(The Wall Street Journal)
Oct-23-23 03:02PM
10:31AM
09:52AM
06:55AM
(The Wall Street Journal)
03:49AM
(The Wall Street Journal)
01:00AM
Oct-13-23 08:00AM
Oct-05-23 05:01AM
Oct-03-23 07:00AM
(The Wall Street Journal)
Sep-30-23 05:00AM
Sep-26-23 06:00AM
Sep-11-23 08:00AM
Sep-09-23 10:51AM
(The Wall Street Journal)
Aug-17-23 04:05PM
Aug-14-23 07:00AM
Aug-03-23 04:05PM
Aug-02-23 04:05PM
Jul-27-23 08:00AM
Jul-26-23 10:21AM
Jul-13-23 05:50PM
(The Wall Street Journal)
Jul-11-23 08:00AM
Jun-28-23 08:57AM
07:00AM
Jun-26-23 04:05PM
Jun-22-23 07:30AM
Jun-21-23 05:00PM
May-16-23 07:00AM
Apr-04-23 07:37AM
07:37AM
Mar-28-23 08:00AM
Mar-15-23 07:45AM
Mar-14-23 04:07PM
08:00AM
Mar-07-23 08:00AM
Feb-21-23 08:32PM
Feb-13-23 04:17PM
(The Wall Street Journal)
+7.77%
07:00AM
Feb-02-23 09:14PM
Feb-01-23 04:05PM
Jan-30-23 08:00AM
Jan-04-23 06:05AM
Dec-07-22 06:30AM
Dec-01-22 08:00AM
Nov-14-22 07:00AM
Nov-10-22 09:00AM
Nov-08-22 06:15AM
Nov-07-22 04:01PM
Oct-18-22 04:00PM
Aug-30-22 07:00AM
Aug-16-22 11:44AM
Aug-15-22 07:00AM
Aug-14-22 10:53AM
Aug-03-22 07:00AM
Jul-23-22 09:00AM
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Venker Eric President & COO Nov 20 '24 Option Exercise 3.85 100,000 385,000 706,525 Nov 22 09:00 PM Venker Eric President & COO Nov 20 '24 Sale 11.32 100,000 1,132,000 606,525 Nov 22 09:00 PM Venker Eric Officer Nov 20 '24 Proposed Sale 11.32 100,000 1,132,008 Nov 20 04:45 PM Venker Eric President & COO Oct 21 '24 Option Exercise 3.85 100,000 385,000 717,470 Oct 22 09:00 PM Venker Eric President & COO Oct 21 '24 Sale 11.65 100,000 1,165,000 617,470 Oct 22 09:00 PM Venker Eric Officer Oct 21 '24 Proposed Sale 11.65 100,000 1,165,393 Oct 21 04:45 PM QVT Financial LP Director by Deputization Sep 26 '24 Sale 11.82 876,000 10,354,320 22,179,358 Sep 26 09:22 PM QVT Financial LP Director by Deputization Sep 25 '24 Sale 11.77 50,000 588,500 23,055,358 Sep 26 09:22 PM MANCHESTER KEITH S Director Sep 24 '24 Sale 11.62 368,052 4,278,604 1,412,126 Sep 26 08:35 PM MANCHESTER KEITH S Director Sep 25 '24 Sale 11.77 134,948 1,587,704 1,277,178 Sep 26 08:35 PM Gold Daniel Allen Director Sep 24 '24 Sale 11.62 1,565,670 18,200,914 5,723,423 Sep 26 08:34 PM Gold Daniel Allen Director Sep 25 '24 Sale 11.77 991,593 11,666,389 4,731,830 Sep 26 08:34 PM Gold Daniel Allen Director Sep 26 '24 Sale 11.82 876,000 10,354,320 22,179,358 Sep 26 08:34 PM Gold Daniel Allen Director Sep 24 '24 Sale 11.62 577,186 6,709,787 2,079,059 Sep 26 08:34 PM Gold Daniel Allen Director Sep 25 '24 Sale 11.77 415,551 4,889,317 1,713,508 Sep 26 08:34 PM BNEI ZAHAV LLC Director Sep 25 '24 Proposed Sale 11.76 23,917 281,264 Sep 25 04:30 PM RIOJA DOLCE LLC Director Sep 25 '24 Proposed Sale 11.76 170,817 2,008,808 Sep 25 04:25 PM KEITH S MANCHESTER REVOCABLE T Director Sep 25 '24 Proposed Sale 11.76 134,948 1,586,988 Sep 25 04:23 PM RIOJA LIETO LLC Director Sep 25 '24 Proposed Sale 11.76 170,817 2,008,808 Sep 25 04:20 PM DANIEL GOLD & LAURA GOLD Director Sep 25 '24 Proposed Sale 11.76 991,593 11,661,134 Sep 25 04:19 PM Gline Matthew CEO Sep 23 '24 Option Exercise 3.85 1,550,000 5,967,500 19,853,800 Sep 24 09:01 PM Gline Matthew CEO Sep 23 '24 Sale 11.79 1,983,257 23,382,600 17,870,543 Sep 24 09:01 PM Kumar Rakhi Chief Accounting Officer Sep 23 '24 Option Exercise 3.85 250,000 962,500 459,322 Sep 24 09:01 PM Kumar Rakhi Chief Accounting Officer Sep 23 '24 Sale 11.89 250,000 2,972,500 209,322 Sep 24 09:01 PM DANIEL GOLD &LAURA GOLD JT TEN Director Sep 24 '24 Proposed Sale 11.62 1,565,670 18,200,914 Sep 24 07:53 PM RIOJA LIETO LLC Director Sep 24 '24 Proposed Sale 11.63 269,712 3,135,402 Sep 24 07:52 PM RIOJA DOLCE LLC Director Sep 24 '24 Proposed Sale 11.63 269,712 3,135,402 Sep 24 07:51 PM BNEI ZAHAV LLC Director Sep 24 '24 Proposed Sale 11.62 37,762 438,983 Sep 24 07:48 PM KEITH S MANCHESTER REVOCABLE T Director Sep 24 '24 Proposed Sale 11.63 368,052 4,281,550 Sep 24 07:43 PM Gline Matthew Officer Sep 23 '24 Proposed Sale 11.79 1,983,257 23,383,088 Sep 23 04:53 PM Kumar Rakhi Officer Sep 23 '24 Proposed Sale 11.89 250,000 2,972,360 Sep 23 04:47 PM Venker Eric President & COO Feb 09 '24 Option Exercise 3.85 96,950 373,258 629,157 Feb 09 09:00 PM Venker Eric President & COO Feb 09 '24 Sale 10.92 96,950 1,058,694 532,207 Feb 09 09:00 PM Ramaswamy Vivek 10% Owner Jan 02 '24 Sale 11.05 3,000,000 33,150,000 51,929,426 Jan 03 04:56 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite